Research programme: islet amyloid polypeptide inhibitors - Innodia

Drug Profile

Research programme: islet amyloid polypeptide inhibitors - Innodia

Alternative Names: ID 1567; NC 935

Latest Information Update: 09 Mar 2009

Price : $50

At a glance

  • Originator Neurochem
  • Developer Innodia
  • Class
  • Mechanism of Action Islet amyloid polypeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Jul 2008 Innodia has been acquired by BELLUS Health
  • 11 Apr 2007 Preclinical development is ongoing
  • 25 Nov 2003 Preclinical trials in Type-2 diabetes mellitus in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top